Evoq Remedies share price
You have to be logged in to add this to Watchlist.- ₹3.49(0.00%)May 9, 2025 16:00:00 PM IST
- NSE
- BSE
- Vol : 0 (NSE + BSE)Last 20 day avg : 30.00 K
Evoq Remedies is trading 0.00% upper at Rs 3.49 as compared to its last closing price. Evoq Remedies has been trading in the price range of 0.00 & 0.00. Evoq Remedies has given -55.26% in this year & 5.44% in the last 5 days. Evoq Remedies has TTM P/E ratio 64.00 as compared to the sector P/E of 24.41.The company posted a net profit of 1.71 Crores in its last quarter.Listed peers of Evoq Remedies include Beryl Drugs (4.09%), Cian Healthcare (1.98%), Evoq Remedies (-%).The Mutual Fund holding in Evoq Remedies was at -% in . The MF holding has - from the last quarter. The FII holding in Evoq Remedies was at -% in . The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on May 13, 2025, 07:24 PM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BLower than historical values0.20The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values87.25Price-to-earnings ratio based on trailing 12-month earnings
- Debt To EquityLower than industry0.00The debt-to-equity ratio, indicating a company's financial leverage.
- Beta-Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is not profitable
The company has grown its March quarter profit by 30.39% from Rs 1.31 crore to Rs 1.71 crore, year-on-year
- R1
- 3.43
- R2
- 3.55
- R3
- 3.61
- S1
- 3.25
- S2
- 3.19
- S3
- 3.07
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Beryl Drugs | Bearish | 19.10 | 4.09 | 9.69 | 11.66 | 0.99 | - | 26.94 |
| Cian Healthcare | Moderately Bullish | 3.61 | 1.98 | 9.02 | 35.17 | 0.15 | - | 47.62 |
| Evoq Remedies | Neutral | 3.49 | - | 8.69 | 87.25 | 0.2 | - | - |
| Vivanza Biosciences | Bearish | 2.10 | -0.94 | 8.40 | 14.86 | 1.79 | - | 57.82 |
| Ortin Global | Neutral | 10.99 | 4.57 | 8.94 | - | 2.94 | - | 63.82 |
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-06 | Preferential issue of shares |
| 2025-04-29 | Others |
| 2025-04-25 | Preferential issue of shares & Others |
| 2025-04-18 | Preferential issue of shares & Others |
| 2025-04-10 | Audited Results |
- IndustryBiotechnology & Drugs
- ISININE0JVD01011
- BSE Code543500
- NSE Code
Evoq Remedies is trading at 3.49 as on Fri May 09 2025 10:30:00. This is 0.00% upper as compared to its previous closing price of 3.49.
The market capitalization of Evoq Remedies is 8.69 Cr as on Fri May 09 2025 10:30:00.
The 52 wk high for Evoq Remedies is 12.28 whereas the 52 wk low is 2.11
Evoq Remedies can be analyzed on the following key metrics -
- TTM P/E: 64.00
- Sector P/E: 24.41
- Dividend Yield: 0.00%
- D/E ratio: 0.00
Evoq Remedies reported a net profit of 0.09 Cr in 2025.